Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis
Leishmaniasis, Cutaneous
About this trial
This is an interventional treatment trial for Leishmaniasis, Cutaneous
Eligibility Criteria
Inclusion Criteria: All participants must be willing to sign informed consent, for patients younger than 18 years old, parents or guardians will sign an informed consent. Patients clinically diagnosed with cutaneous leishmaniasis and confirmed using parasitological Giemsa-stained direct smears. Acute lesions of less than 12-week duration to exclude any possibility of natural self-healing of the lesions during follow-up. Both sexes. Age: > 12 years old. Exclusion Criteria: • Pregnancy and lactation. Patients < 12 years old. Patients with negative Giemsa stained direct smears. Patients with concomitant renal or liver impairment, congestive heart failure, uncontrolled diabetes mellitus, peripheral neuropathy, poor peripheral circulation, and prolonged corticosteroid therapy. Patients with lesions of more than 12 weeks duration. Patients with lesions > 5cm2 History of anti-Leishmania therapy in the last 3 months. For the intralesional groups the presence of > 5 lesions. Lesions in the perimeter (< 2 cm) of mucosal areas e.g. eyes, nose, mouth, or genitals. Patients with known hypersensitivity or allergy to the assigned drugs.
Sites / Locations
- Dermatology department, Gharyan University Hospitals, Medical College, Gharyan UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Experimental
Experimental
Experimental
Intralesional Sodium stibogluconate
intralesional Cryotherapy
Intralesional Voriconazole
Oral doxycycline
Patients will receive intralesional infiltration of (SSG) at a dose of 50 mg/0.5 ml (0.2-0.4ml) maximum dose per session 1-3 ml. Sessions will be held once weekly for a maximum of 6 weeks.
Patients will be treated with intralesional Cryotherapy. Sessions will be held every two weeks till complete cure or a maximum of 6 sessions
Patients will be treated with intralesional Voriconazole weekly till complete cure or a maximum of 6 sessions
Patients will be treated with oral doxycycline, 200 mg daily, until complete cure or a maximum of 6 weeks